Methylated TIMP-3 DNA in body fluids is an independent prognostic factor for gastric cancer

Archives of Pathology and Laboratory Medicine

Volumn 138, Issue 11, 2014, Pages 1466-1473

  Yu, Jiang Liu ^a   Lv, Ping ^b   Han, Jing ^a   Zhu, Xin ^a   Hong, Lian Lian ^a   Zhu, Wang Yu ^b   Wang, Xin Bao ^a   Wu, Yi Chen ^a   Li, Pei ^c   Ling, Zhi Qiang ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b Zhoushan Hospital   (China)

^c ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; TIMP3 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR MARKER;

ADULT; AGED; ASCITES FLUID; BLOOD; DISEASE COURSE; DNA METHYLATION; DOWN REGULATION; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; STOMACH TUMOR;

ADULT; AGED; ASCITIC FLUID; DISEASE PROGRESSION; DNA METHYLATION; DNA, NEOPLASM; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; STOMACH NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TUMOR MARKERS, BIOLOGICAL;

EID: 84923887072     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2013-0285-OA     Document Type: Article

References (42)

1. Corso G, Seruca R, Roviello F. Gastric cancer carcinogenesis and tumor progression. Ann Ital Chir. 2012;83(3):172-176.
2. Lambert R, Saito H, Lucas E, Sankaranarayanan R. Survival from digestive cancer in emerging countries in Asia and Africa. Eur J Gastroenterol Hepatol. 2012;24(6):605-612.
3. Key TJ, Schatzkin A, Willett WC, Allen NE, Spencer EA, Travis RC. Diet, nutrition and the prevention of cancer. Public Health Nutr. 2004;7(1A):187-200.
4. Chen J, Bu XL, Wang QY, Hu PJ, Chen MH. Decreasing seroprevalence of Helicobacter pylori infection during 1993-2003 in Guangzhou, southern China. Helicobacter. 2007;12(2):164-169.
5. Kawakami E, Machado RS, Ogata SK, Langner M. Decrease in prevalence of Helicobacter pylori infection during a 10-year period in Brazilian children. Arq Gastroenterol. 2008;45(2):147-151.
6. Tkachenko MA, Zhannat NZ, Erman LV, et al. Dramatic changes in the prevalence of Helicobacter pylori infection during childhood: a 10-year follow-up study in Russia. J Pediatr Gastroenterol Nutr. 2007;45(4):428-432.
7. Kwon JY, Yun J, Kim HJ, et al. Clinical outcome of gastric cancer patients with bone marrow metastases. Cancer Res Treat. 2011;43(4):244-249.
8. Thiel A, Ristimäki A. Gastric cancer: basic aspects. Helicobacter. 2012;17(suppl 1):26-29.
9. Lee JH, Kim KM, Cheong JH, Noh SH. Current management and future strategies of gastric cancer. Yonsei Med J. 2012;53(2):248-257.
10. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 2010;29(1):181-206.
11. Ibáñez de Cáceres I, Cairns P. Methylated DNA sequences for early cancer detection, molecular classification and chemotherapy response prediction. Clin Transl Oncol. 2007;9(7):429-437.
12. Fiegl H, Elmasry K. Cancer diagnosis, risk assessment and prediction of therapeutic response by means of DNA methylation markers. Dis Markers. 2007;23(1-2):89-96.
13. Zhou J, Shi YH, Fan J. Circulating cell-free nucleic acids: promising biomarkers of hepatocellular carcinoma. Semin Oncol. 2012;39(4):440-448.
14. Breitbach S, Tug S, Simon P. Circulating cell-free DNA: an up-coming molecular marker in exercise physiology. Sports Med. 2012;42(7):565-586.
15. Li L, Choi JY, Lee KM, et al. DNA methylation in serum: a potential biomarker for cancer molecular epidemiology. J Epidemiol. 2012;22(5):384-394.
16. Roos PH, Jakubowski N. Methods for the discovery of low-abundance biomarkers for urinary bladder cancer in biological fluids. Bioanalysis. 2010;2(2):295-309.
17. Sriram KB, Relan V, Clarke BE, et al. Diagnostic molecular biomarkers for malignant pleural effusions. Future Oncol. 2011;7(6):737-752.
18. Wu T, Giovannucci E, Welge J, Mallick P, Tang WY, Ho SM. Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Br J Cancer. 2011;105(1):65-73.
19. Barski D, Wolter M, Reifenberger G, Riemenschneider MJ. Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol. 2010;20(3):623-631.
20. Apte SS, Olsen BR, Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem. 1995;270(24):14313-14318.
21. Lin H, Zhang Y, Wang H, et al. Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells. Cancer Gene Ther. 2012;19(12):845-851.
22. Bernot D, Barruet E, Poggi M, Bonardo B, Alessi MC, Peiretti F. Down-regulation of tissue inhibitor of metalloproteinase-3 (TIMP-3) expression is necessary for adipocyte differentiation. J Biol Chem. 2010;285(9):6508-6514.
23. Menghini R, Menini S, Amoruso R, et al. Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology. 2009;136(2):663-672.
24. Sun W, Zaboli D, Wang H, et al. Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer. Clin Cancer Res. 2012;18(4):1082-1091.
25. Liu WB, Cui ZH, Ao L, et al. Aberrant methylation accounts for cell adhesion-related gene silencing during 3-methylcholanthrene and diethylnitrosamine induced multistep rat lung carcinogenesis associated with overexpression of DNA methyltransferases 1 and 3a. Toxicol Appl Pharmacol. 2011;251(1):70-78.
26. Luebke T, Baldus SE, Grass G, et al. Histological grading in gastric cancer by Ming classification: correlation with histopathological subtypes, metastasis, and prognosis. World J Surg. 2005;29(11):1422-1427.
27. Yu QM, Wang XB, Luo J, et al. CDH1 methylation in preoperative peritoneal washes is an independent prognostic factor for gastric cancer. J Surg Oncol. 2012;106(6):765-771.
28. Tian XY, Zhu H, Zhao J, She Q, Zhang GX. Diagnostic performance of urea breath test, rapid urea test, and histology for Helicobacter pylori infection in patients with partial gastrectomy: a meta-analysis. J Clin Gastroenterol. 2012;46(4):285-292.
29. Shinojima T, Yu Q, Huang SK, et al. Heterogeneous epigenetic regulation of TIMP-3 in prostate cancer. Epigenetics. 2012;7(11):1279-1289.
30. Lu XX, Yu JL, Ying LS, et al. Stepwise cumulation of RUNX3 methylation mediated by Helicobacter pylori infection contributes to gastric carcinoma progression. Cancer. 2012;118(22):5507-5517.
31. Ling ZQ, Tanaka A, Li P, et al. Microsatellite instability with promoter methylation and silencing of hMLH1 can regionally occur during progression of gastric carcinoma. Cancer Lett. 2010;297(2):244-251.
32. Ge MH, Chen C, Xu JJ, Ling ZQ. Critical regions and spreading of runt-related transcription factor-3 C-phosphate-G (CpG) island methylation in human salivary gland adenoid cystic carcinoma. Hum Pathol. 2011;42(12):1862-1872.
33. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 2000;89(12):2637-2645.
34. Ling ZQ, Lv P, Lu XX, et al. Circulating methylated XAF1 DNA indicates poor prognosis for gastric cancer. PLoS One. 2013;8(6):e67195.
35. Brait M, Loyo M, Rosenbaum E, et al. Correlation between BRAF mutation and promoter methylation of TIMP3, RARb2 and RASSF1A in thyroid cancer. Epigenetics. 2012;7(7):710-719.
36. Liu BL, Cheng JX, Zhang W, et al. Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro-oncol. 2010;12 (6):540-548.
37. Ninomiya I, Kawakami K, Fushida S, et al. Quantitative detection of TIMP-3 promoter hypermethylation and its prognostic significance in esophageal squamous cell carcinoma. Oncol Rep. 2008;20(6):1489-1495.
38. Wang Y, Zhang D, Zheng W, Luo J, Bai Y, Lu Z. Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer. 2008;112(6):1325-1336.
39. Gu P, Xing X, Tänzer M, et al. Frequent loss of TIMP-3 expression in progression of esophageal and gastric adenocarcinomas. Neoplasia. 2008;10(6):563-572.
40. Chang MS, Uozaki H, Chong JM, et al. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res. 2006;12(10):2995-3002.
41. Kim JH, Jung EJ, Lee HS, Kim MA, Kim WH. Comparative analysis of DNA methylation between primary and metastatic gastric carcinoma. Oncol Rep. 2009;21(5):1251-1259.
42. Shin SH, Park SY, Ko JS, Kim N, Kang GH. Aberrant CpG island hypermethylation in pediatric gastric mucosa in association with Helicobacter pylori infection. Arch Pathol Lab Med. 2011;135(6):759-765.